Mark Genovese
Corporate Officer/Principal bij ELI LILLY AND COMPANY
Profiel
Mark Genovese is currently the Senior Vice President-Immunology Development at Eli Lilly & Co. He previously worked as the Director at Kyverna Therapeutics, Inc. and as the Clinical Chief-Immunology & Rheumatology at Stanford University.
From 2020 to 2023, he served as the Senior Vice President-Inflammation Development at Gilead Sciences, Inc. Dr. Genovese completed his undergraduate degree at the University of Notre Dame and obtained his doctorate from The Johns Hopkins University School of Medicine.
Actieve functies van Mark Genovese
| Bedrijven | Functie | Begin |
|---|---|---|
| ELI LILLY AND COMPANY | Corporate Officer/Principal | 16-10-2023 |
Eerdere bekende functies van Mark Genovese
| Bedrijven | Functie | Einde |
|---|---|---|
| GILEAD SCIENCES, INC. | Corporate Officer/Principal | 01-09-2023 |
| KYVERNA THERAPEUTICS, INC. | Director/Board Member | - |
| Stanford University | Corporate Officer/Principal | - |
Opleiding van Mark Genovese
| University of Notre Dame | Undergraduate Degree |
| The Johns Hopkins University School of Medicine | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 3 |
|---|---|
| GILEAD SCIENCES, INC. | Health Technology |
| ELI LILLY AND COMPANY | Health Technology |
| KYVERNA THERAPEUTICS, INC. | Health Technology |
